Leerink Partners Sticks to Its Buy Rating for Xenon (XENE)
at www.tipranks.com (Wed, 24-Jun 7:26 AM)
Xenon's Azetukalner Achieves Breakthrough Seizure Control in Phase 3 X-TOLE2 Study—Nearly 40% Achieve Year-Long Freedom After Four Years
Market Chameleon (Mon, 20-Apr 9:39 AM)
